Skip to main content
NCBI home page
Gut logoLink to Gut
. 1978 Feb;19(2):91–94. doi: 10.1136/gut.19.2.91

Treatment of HBsAg-positive chronic active hepatitis with human fibroblast interferon.

J G Kingham, N K Ganguly, Z D Shaari, R Mendelson, M J McGuire, S J Holgate, T Cartwright, G M Scott, B M Richards, R Wright
PMCID: PMC1411823  PMID: 631632

Abstract

Two patients with HBsAg positive chronic active hepatitis have been treated with human fibroblast interferon 10(7) units daily for two weeks. Before treatment, both patients had high levels of hepatitis B surface antigen, core antibody, and DNA-binding antibody in the blood and one patient had a fourfold rise in serum AST. During treatment there was a striking fall in the core antibody titre and also in the DNA-binding antibody, which has been maintained for several months subsequently; in one patient the initially high AST level fell to normal. No significant adverse effects occurred, and these observations should encourage further trials of fibroblasts interferon in hepatitis B.

Full text

PDF
91

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Carr R. I., Koffler D., Agnello V., Kunkel H. G. Studies on DNA antibodies using DNA labelled with actinomycin-D (3H) or dimethyl (3H) sulphate. Clin Exp Immunol. 1969 May;4(5):527–536. [PMC free article] [PubMed] [Google Scholar]
  2. Desmyter J., De Groote J., Desmet V. J., Billiau A., Ray M. B., Bradburne A. F., Edy V. G., De Somer P. Administration of human fibroblast interferon in chronic hepatitis-B infection. Lancet. 1976 Sep 25;2(7987):645–647. doi: 10.1016/s0140-6736(76)92460-0. [DOI] [PubMed] [Google Scholar]
  3. Greenberg H. B., Pollard R. B., Lutwick L. I., Gregory P. B., Robinson W. S., Merigan T. C. Effect of human leukocyte interferon on hepatitis B virus infection in patients with chronic active hepatitis. N Engl J Med. 1976 Sep 2;295(10):517–522. doi: 10.1056/NEJM197609022951001. [DOI] [PubMed] [Google Scholar]
  4. Hung P. P., Mao J. C., Ling C. M., Overby L. R. Hybridisation of Dane particle DNA with the free plasma DNA of hepatitis carriers. Nature. 1975 Feb 13;253(5492):571–572. doi: 10.1038/253571a0. [DOI] [PubMed] [Google Scholar]
  5. Jain S., Markham R., Thomas H. C., Sherlock S. Double-stranded DNA-binding capacity of serum in acute and chronic liver disease. Clin Exp Immunol. 1976 Oct;26(1):35–41. [PMC free article] [PubMed] [Google Scholar]
  6. Nielsen J. O., Dietrichson O., Juhl E. Incidence and meaning of the "e" determinant among hepatitis-B-antigen positive patients with acute and chronic liver diseases. Report from the Copenhagen Hepatitis Acuta Programme. Lancet. 1974 Oct 19;2(7886):913–915. doi: 10.1016/s0140-6736(74)91127-1. [DOI] [PubMed] [Google Scholar]
  7. Nordenfelt E., Kjellén L. Dane particles, DNA polymerase, and e-antigen in two different categories of hepatitis B antigen carriers. Intervirology. 1975;5(3-4):225–232. doi: 10.1159/000149918. [DOI] [PubMed] [Google Scholar]
  9. Purcell R. H., London W. T., McAuliffe V. J., Palmer A. E., Kaplan P. M., Gerin J. L., Wagner J., Popper H., Lvovsky E., Wong D. C. Modification of chronic hepatitis-B virus infection in chimpanzees by administration of an interferon inducer. Lancet. 1976 Oct 9;2(7989):757–761. doi: 10.1016/s0140-6736(76)90598-5. [DOI] [PubMed] [Google Scholar]
  10. Sehgal P. B., Tamm I., Vilcek J. On the mechanism of enhancement of human interferon production by actinomycin D and cycloheximide. Virology. 1976 Mar;70(1):256–259. doi: 10.1016/0042-6822(76)90267-1. [DOI] [PubMed] [Google Scholar]
  11. Wright R. The Australia antigen in chronic active hepatitis. Vox Sang. 1970 Sep-Oct;19(3):320–326. [PubMed] [Google Scholar]

Articles from Gut are provided here courtesy of BMJ Publishing Group

RESOURCES